Argenica Therapeutics (ASX:AGN) said the independent Data Safety Monitoring Board recommended that the phase two clinical trial of neuroprotective peptide drug candidate, ARG-007, in acute ischaemic stroke patients continue with no modification, according to a Thursday filing with the Australian bourse.
The board reviewed the safety data of the first 76 patients dosed in Argenica's phase two trial, which represents a review of 83% of patients in the study.
The board is an independent multidisciplinary committee consisting of an independent chairperson neurologist, two additional independent neurologists, and a biostatistician with relevant clinical trial experience.
Dosing is 86% complete, with 79 patients dosed in the phase two trial, with eight of the 10 activated hospitals having dosed patients, according to the filing. Dosing of all 92 patients is expected to be completed in the second quarter.
The firm's shares rose past 4% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。